Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in … Read more
Annexon Inc (ANNX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.324x
Based on the latest financial reports, Annexon Inc (ANNX) has a cash flow conversion efficiency ratio of -0.324x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.30 Million) by net assets ($161.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Annexon Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Annexon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Annexon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annexon Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dateline Resources Ltd
AU:DTR
|
-0.212x |
|
Interfor Corporation
PINK:IFSPF
|
-0.001x |
|
Fuxin Dare Automotive Parts Co Ltd
SHE:300473
|
0.063x |
|
Scientech Corp
TW:3583
|
0.055x |
|
Guangzhou Risong Intelligent Technology Holding Co Ltd
SHG:688090
|
0.050x |
|
Care Property Invest NV
BR:CPINV
|
0.000x |
|
ADENTRA INC.
F:UQ0
|
N/A |
|
Integra LifeSciences Holdings
NASDAQ:IART
|
0.039x |
Annual Cash Flow Conversion Efficiency for Annexon Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Annexon Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $293.11 Million | $-118.01 Million | -0.403x | +16.73% |
| 2023-12-31 | $250.56 Million | $-121.14 Million | -0.483x | +3.89% |
| 2022-12-31 | $231.19 Million | $-116.31 Million | -0.503x | -9.95% |
| 2021-12-31 | $231.91 Million | $-106.11 Million | -0.458x | -196.73% |
| 2020-12-31 | $344.28 Million | $-53.09 Million | -0.154x | +76.33% |
| 2019-12-31 | $43.53 Million | $-28.36 Million | -0.651x | -43.56% |
| 2018-12-31 | $37.88 Million | $-17.19 Million | -0.454x | -208.88% |
| 2017-12-31 | $-46.21 Million | $-19.26 Million | 0.417x | -- |